Cargando…

Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan

OBJECTIVES: To determine whether anticoagulation therapy improves outcomes in patients with coronavirus disease 2019 (COVID-19) in Japan given their lower risk of thrombosis compared with Western cohorts. METHODS: The efficacy of anticoagulation therapy in hospitalized patients with COVID-19 was eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hara, Hisao, Uemura, Yukari, Hayakawa, Kayoko, Togano, Tomiteru, Asai, Yusuke, Matsunaga, Nobuaki, Terada, Mari, Ohtsu, Hiroshi, Kitajima, Koji, Shimizu, Yousuke, Sato, Lubna, Ishikane, Masahiro, Kinoshita-Iwamoto, Noriko, Shibata, Taro, Kondo, Masashi, Izumi, Kazuo, Sugiura, Wataru, Ohmagari, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432973/ https://www.ncbi.nlm.nih.gov/pubmed/34517044 http://dx.doi.org/10.1016/j.ijid.2021.09.014

Ejemplares similares

The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan
por: Togano, Tomiteru, et al.
Publicado: (2021)

Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study
por: Matsunaga, Nobuaki, et al.
Publicado: (2022)

Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan
por: Terada, Mari, et al.
Publicado: (2021)

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan
por: Matsunaga, Nobuaki, et al.
Publicado: (2020)

Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics
por: Saito, Sho, et al.
Publicado: (2021)

Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control
por: Uemura, Yukari, et al.
Publicado: (2023)

Predicting respiratory failure for COVID-19 patients in Japan: a simple clinical score for evaluating the need for hospitalisation
por: Yamada, Gen, et al.
Publicado: (2021)

Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan
por: Yoshihara, Fumiki, et al.
Publicado: (2022)

2032. First National Survey of Antimicrobial and Antifungal Stewardship in Japan
por: Moriyama, Yuki, et al.
Publicado: (2019)

Nationwide cross-sectional study of antimicrobial stewardship and antifungal stewardship programs in inpatient settings in Japan
por: Moriyama , Yuki, et al.
Publicado: (2021)

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals
por: Terada, Mari, et al.
Publicado: (2023)

Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities
por: Tomidokoro, Daiki, et al.
Publicado: (2023)

Risk factors associated with asymptomatic hypoxemia among COVID-19 patients: a retrospective study using the nationwide Japanese registry, COVIREGI-JP
por: Akiyama, Yutaro, et al.
Publicado: (2022)

External validation and update of prediction models for unfavorable outcomes in hospitalized patients with COVID-19 in Japan
por: Yamada, Gen, et al.
Publicado: (2021)

223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
por: Endo, Mio, et al.
Publicado: (2020)

908. Evaluation of Blood Culture Submission Rates in Japan
por: Tajima, Taichi, et al.
Publicado: (2020)

We Should Pay More Attention to Sex Differences to Predict the Risk of Severe COVID-19: Men Have the Same Risk of Worse Prognosis as Women More Than 10 Years Older
por: Matsushita, Yumi, et al.
Publicado: (2023)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

1182. Risk Factors for the Acquisition of IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan: A Matched Case–control Study
por: Saito, Sho, et al.
Publicado: (2018)

1193. Comparison of the Clinical Outcomes of Patients With IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenem-Sensitive Enterobacteriaceae in Japan
por: Saito, Sho, et al.
Publicado: (2018)

Longitudinal trends of and factors associated with inappropriate antibiotic prescribing for non-bacterial acute respiratory tract infection in Japan: A retrospective claims database study, 2012–2017
por: Kimura, Yuki, et al.
Publicado: (2019)

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)
por: Tomita, Noriko, et al.
Publicado: (2022)

Predictors of silent hypoxia in hospitalized patients with COVID-19 in Japan
por: Hayakawa, Kayoko, et al.
Publicado: (2022)

Epidemiology of Blood Stream Infection due to Candida Species in a Tertiary Care Hospital in Japan over 12 Years: Importance of Peripheral Line-Associated Candidemia
por: Ishikane, Masahiro, et al.
Publicado: (2016)

The impact of infectious disease consultation in candidemia in a tertiary care hospital in Japan over 12 years
por: Ishikane, Masahiro, et al.
Publicado: (2019)

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial
por: Terada-Hirashima, Junko, et al.
Publicado: (2020)

Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan
por: Nomoto, Hidetoshi, et al.
Publicado: (2022)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan
por: Suzuki, Tetsuya, et al.
Publicado: (2022)

Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test
por: Suzuki, Michiyo, et al.
Publicado: (2023)

1785. Regional Variation of Antimicrobial Use in Japan From 2013 to 2016
por: Kusama, Yoshiki, et al.
Publicado: (2018)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

1147. Regional Trends in Favipiravir and Steroid Use in the Treatment of COVID-19
por: Asai, Yusuke, et al.
Publicado: (2022)

The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan
por: Kamo-Imai, Ayumi, et al.
Publicado: (2023)

Effect of evacuation of Japanese residents from Wuhan, China, on preventing transmission of novel coronavirus infection: A modelling study
por: Asai, Yusuke, et al.
Publicado: (2021)

480. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant among Immunocompromised Patients
por: KAMEGAI, K O H E I, et al.
Publicado: (2023)

Difficulty of downscaling the precautions for coronavirus disease-19 based on negative throat polymerase chain results in the early phase of infection()
por: Suzuki, Tetsuya, et al.
Publicado: (2020)

Predictive model of risk factors of High Flow Nasal Cannula using machine learning in COVID-19
por: Matsunaga, Nobuaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6brstta3mc5aaoom9agqsbeb3m